

# Mohsen Farsad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6030790/publications.pdf>

Version: 2024-02-01

61  
papers

2,802  
citations

257450

24  
h-index

189892

50  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1076-1084.	2.8	674
2	Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and <sup>11</sup> C-Choline PET/CT. <i>Radiology</i> , 2007, 244, 797-806.	7.3	193
3	Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1642-9.	5.0	178
4	Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. <i>Nuclear Medicine Communications</i> , 2007, 28, 589-595.	1.1	168
5	The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer's dementia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1690-1695.	7.1	164
6	<sup>11</sup> C-Choline Positron Emission Tomography/Computerized Tomography for Tumor Localization of Primary Prostate Cancer in Comparison With 12-Core Biopsy. <i>Journal of Urology</i> , 2006, 176, 954-960.	0.4	144
7	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 525-531.	6.4	135
8	<sup>11</sup> C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 68.	1.9	97
9	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. <i>Nuclear Medicine Communications</i> , 2005, 26, 689-694.	1.1	88
10	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , 2007, 92, 771-777.	3.5	74
11	18F-FDG PET in malignant lymphoma: significance of positive findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 749-756.	6.4	62
12	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2096-2101.	1.3	54
13	<sup>11</sup> C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 453-459.	6.4	49
14	18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. <i>Radiologia Medica</i> , 2006, 111, 1146-1155.	7.7	47
15	Role of <sup>18</sup> F-FDG-PET and PET/CT imaging in thyroid cancer. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 409-413.	5.6	46
16	Role of 18F-dopa PET/CT imaging in the management of patients with <sup>111</sup> In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007, 28, 473-477.	1.1	45
17	Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 291-295.	1.4	44
18	Value of Fused <sup>18</sup> F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	44

#	ARTICLE	IF	CITATIONS
19	Somatostatin Receptor Scintigraphy for Bronchial Carcinoid Follow-Up. <i>Clinical Nuclear Medicine</i> , 2003, 28, 548-552.	1.3	32
20	18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 593-606.	5.6	32
21	Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. <i>Nuclear Medicine Communications</i> , 2005, 26, 827-830.	1.1	31
22	Role of 18F-FDG PET for Evaluating Malignant Pleural Mesothelioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 149-154.	1.0	30
23	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009, 95, 382-384.	1.1	28
24	FDG PET/CT in the Staging of Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 195-203.	0.8	28
25	A simple Tracerlab module modification for automated on-column [11C]methylation and [11C]carboxylation. <i>Applied Radiation and Isotopes</i> , 2007, 65, 691-695.	1.5	25
26	FDG small animal PET permits early detection of malignant cells in a xenograft murine model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 755-762.	6.4	25
27	11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1704-1705.	6.4	25
28	<sup>18</sup> F-FDG PET Early After Radiotherapy in Lymphoma Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 606-612.	1.0	24
29	C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 659-665.	1.3	21
30	Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding. <i>Cancer Imaging</i> , 2006, 6, 20-23.	2.8	21
31	Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1522-1522.	6.4	17
32	Thromboembolism in Pulmonary Artery Sarcoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 239-240.	1.3	17
33	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1898-1907.	6.4	17
34	Reliability and reproducibility of N-[11C]methyl-choline and L-(S-methyl-[11C])methionine solid-phase synthesis: a useful and suitable method in clinical practice. <i>Nuclear Medicine Communications</i> , 2008, 29, 736-740.	1.1	14
35	Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients. <i>Chemotherapy</i> , 2008, 54, 421-424.	1.6	13
36	Artefacts of PET/CT images. <i>Biomedical Imaging and Intervention Journal</i> , 2006, 2, e60.	0.5	13

#	ARTICLE	IF	CITATIONS
37	Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia. International Archive of Medicine, 2011, 4, 22.	1.2	12
38	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1908-1914.	6.4	12
39	Non-FDG PET/CT in Diagnostic Oncology: a pictorial review. European Journal of Hybrid Imaging, 2019, 3, 20.	1.5	10
40	Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. Annals of Hematology, 2013, 92, 121-123.	1.8	9
41	FDG PET/CT in Malignant Eccrine Porocarcinoma Arising in a Pre-existing Poroma. Clinical Nuclear Medicine, 2014, 39, 456-458.	1.3	7
42	Lifelong bilingualism and mechanisms of neuroprotection in Alzheimer dementia. Human Brain Mapping, 2022, 43, 581-592.	3.6	7
43	10-Year Clinical Experience With 18F-Choline PET/CT. Clinical Nuclear Medicine, 2020, 45, 594-603.	1.3	6
44	Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. Leukemia and Lymphoma, 2006, 47, 1048-1052.	1.3	5
45	Clinical Aspects, Diagnostic Challenges and Management of Patients with Neuroendocrine Tumors (NETs). Onkologie, 2011, 34, 139-146.	0.8	4
46	Imaging with 11Carbon labelled PET tracers. Nuclear Medicine Communications, 2010, 31, 613-616.	1.1	3
47	<sup>18</sup> F-DOPA and <sup>18</sup> F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports. Current Radiopharmaceuticals, 2014, 7, 133-137.	0.8	3
48	Economic sanctions are against basic human rights on health. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1046-1047.	6.4	2
49	Scintigraphic Findings in Necrotizing Myopathy. Clinical Nuclear Medicine, 2003, 28, 118-120.	1.3	1
50	Acetate PET-CT. , 2010, , 123-143.		1
51	394 DIFFERENTIAL DIAGNOSIS BETWEEN FOCAL NODULAR HYPERPLASIA AND HEPATOCELLULAR ADENOMA: POTENTIAL ROLE OF DOUBLE TRACER PET WITH 11C-ACETATE AND 18F-FDG. Journal of Hepatology, 2008, 48, S153.	3.7	0
52	Choline PET-CT. , 2010, , 13-47.		0
53	Cancers of Unknown Origin. , 2018, , 319-328.		0
54	Infection and Inflammation. , 2018, , 331-346.		0

#	ARTICLE	IF	CITATIONS
55	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). Clinical and Translational Imaging, 2020, 8, 29-38.	2.1	0
56	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. Blood, 2005, 106, 3492-3492.	1.4	0
57	Head and Neck Malignancies. , 2018, , 167-191.		0
58	Malignancy in Orthopedics. , 2018, , 305-318.		0
59	Premises to PET/CT with FDG in Oncology. , 2018, , 3-17.		0
60	Malignancies of Lower Gastroenterological Tract. , 2018, , 259-290.		0
61	Malignancies in Hematology. , 2018, , 77-101.		0